MYRIAD GENETICS INC (MYGN): Results of Operations and Financial Condition
MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991mygn-xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability Highl ights • Second quarter 2026 revenue of $190.
How this was made
The 30-second read
Why it matters
Traders can update models around 2026 revenue, margin, and cash-flow trajectory based on the disclosed Q2 performance drivers and the company’s stated guidance revision assumptions for the second half of 2026.
Market read
Guidance revision plus disclosed declines in Prenatal Health volumes and average revenue per test are likely the primary catalysts for repricing, partially offset by Cancer Care Continuum growth and product expansion.
What to watch
The filing attributes part of revenue pressure to estimate changes for cash collections and prior-period performance obligations, so investors should separate underlying demand from accounting/collections timing effects.
Background
The filing is an SEC 8-K with an earnings release (Item 2.02) covering Q2 2026 financials, operational highlights, and a revised 2026 outlook.
Ticker impact
Myriad Genetics reported Q2 2026 results and revised full-year 2026 guidance, citing lower Prenatal Health volumes and payer friction.
Bias to downside or higher volatility until investors gain clarity on Prenatal Health volume recovery and payer reimbursement normalization.
Revenue fell 11% YoY, average revenue per test declined 9%, gross margin fell 460 bps, and adjusted free cash flow was negative, alongside explicit guidance revision for 2026.
Market effects
Signals ongoing reimbursement friction and volume volatility in molecular diagnostics, which can affect sentiment toward precision oncology testing peers.
Limited direct regional read-through; primarily US payer reimbursement dynamics.
Modest, as the disclosed initiatives and payer dynamics are largely US-focused, though oncology assay validation is globally relevant.
Counterpoint
Cancer Care Continuum momentum (6% volume growth, Prolaris + AI launch, Precise MRD expansion) could offset Prenatal Health weakness faster than the market expects.
Key entities
- issuerMyriad Genetics, Inc.
Reported Q2 2026 results, launched Prolaris + AI, expanded Precise MRD, and revised full-year 2026 financial guidance.
- executiveSam Raha
CEO quoted on Q2 performance drivers, strategic review, and the Ascend efficiency initiative.
